항정신병약 : 시장 인사이트, 경쟁 구도, 시장 예측(2030년)

Antipsychotic Drugs Market by Indication (Schizophrenia, Bipolar Disorder, Unipolar Disorder, Dementia, and Others), Drug Class (First Generation or Typical Antipsychotics [Haloperidol, Prochlorperazine, and Others], Second Generation or Atypical Antipsychotics [Clozapine, Risperidone, and Others], Third Generation [Abilify and Others], Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and E-Commerce), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing burden of mental disorders such as schizophrenia, dementia & others, and the increasing research & developmental activities in antipsychotic drugs across the globe

The antipsychotic drugs market was valued at USD 13,404.76 million in 2023 and is likely to register a CAGR of 6.62% during the forecast period from 2024 to 2030 to reach USD 19,653.29 million by 2030. The antipsychotic drugs market is observing substantial market growth due to the growing prevalence of mental disorders such as schizophrenia, schizoaffective disorder, bipolar disorder, severe depression, psychotic symptoms of a personality disorder, and others. The increasing geriatric population base prone to mental disorders, the increasing focus of governments and healthcare organizations on mental health, and others will aid in surging the demand for antipsychotic drugs. Moreover, the rising research & developmental activities along with the surging drug approvals and launches in the market will create a requisite for antipsychotic drugs owing to which the market is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

Antipsychotic Drugs Market Dynamics:

The World Health Organization (WHO) in 2022, stated that depression is a common illness worldwide, with an estimated 3.8% of the population affected, including 5.0% among adults and 5.7% among adults older than 60 years. Also, it stated that nearly 40 million people experienced bipolar disorder and 40 million people, including children and adolescents were living with conduct-dissocial disorder.

From the above statistics, it can be concluded that the prevalence of mental disorders is high across the globe, ultimately increasing the demand for antipsychotic drugs, engaged in the treatment of the above-mentioned disorders.

Furthermore, the latest approvals in the antipsychotic drugs market will push forward its revenue shares in the market. For example, In April 2023, Otsuka America Pharmaceutical, Inc. and Lundbeck announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application for ABILIFY ASIMTUFII (aripiprazole) extended-release injectable suspension for intramuscular use. This formulation is a once-every-two-months injection indicated for the treatment of schizophrenia in adults and as maintenance monotherapy for bipolar I disorder in adults.

Moreover, the clinical trials of antipsychotic drugs are expected to significantly advance the drug development process. For instance, Karuna Therapeutics is advancing its product pipeline by introducing novel drug candidates such as KarXT (xanomeline-trospium) for the treatment of various psychiatric and neurological conditions. Currently, the candidate is being evaluated in late-stage clinical trials as a potential treatment for schizophrenia and psychosis in Alzheimer's disease. In October 2022, the company also announced the data of its Phase III clinical trials.

Thus, the surging awareness, combined with new launches based on innovative R&D, is expected to drive the market growth for antipsychotic drugs during the forecast period. Therefore, all the factors stated above collectively will drive the overall antipsychotic drugs market throughout the forecast period from 2024 to 2030.

However, the high cost of drug development and launches, addiction caused due to antipsychotic drugs, and the stringent regulatory approval process may halt the market growth of antipsychotic drugs.

Antipsychotic Drugs Market Segment Analysis:

Antipsychotic Drugs Market by Indication (Schizophrenia, Bipolar Disorder, Unipolar Disorder, Dementia, and Others), Drug Class (First Generation or Typical Antipsychotics [Haloperidol, Prochlorperazine, and Others], Second Generation or Atypical Antipsychotics [Clozapine, Risperidone, and Others], Third Generation [Abilify and Others], Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and E-Commerce), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the indication segment of the antipsychotic drugs market, the schizophrenia category is expected to have a significant revenue share in the year 2023. This iss primarily owing to the increasing prevalence of schizophrenia across the globe. Also, the expanding launches and strategic investments, and other activities by key players in the segment will support the market growth during the forecast period.

For instance, as per the WHO statistics in 2022, it stated that schizophrenia affects approximately 24 million people or 1 in 300 people (0.32%) worldwide and this rate is 1 in 222 people (0.45%) among adults on an average. Its onset is most often during late adolescence and the twenties, and the onset tends to happen earlier among men than among women.

Further, as per a recent study done by the National Alliance on Mental Illness, nearly 1.5 million people yearly suffer from schizophrenia, in the US. The same source stated that at some time during their life, about 1 in 100 people will suffer an episode of schizophrenia.

Moreover, the presence of a robust number of schizophrenia-treating antipsychotic drugs in the pipeline is also expected to drive its market growth. For instance, in February 2022, Alkermes plc received positive results from ENLIGHTEN-Early, a phase 3b study that assessed the effect of LYBALVI (olanzapine and samidorphan) compared to olanzapine on body weight in young adult patients (age 16 to 39; mean age: 26 years) with schizophrenia, schizophreniform disorder or bipolar I disorder.

Various other strategic steps taken by key players in the market will also help in driving the market growth of antipsychotics. For instance, in January 2022, Otsuka America Pharmaceutical, Inc. and H. Lundbeck A/S received the U.S. FDA approval for the supplemental new drug application (sNDA) of REXULTI (brexpiprazole) for the treatment of schizophrenia in pediatric patients from ages 13 to 17.

Therefore, owing to the above-mentioned factors, the demand for schizophrenia-treating antipsychotic drugs will upsurge, due to which this category is expected to witness considerable growth, eventually contributing to the growth of the overall antipsychotic drugs market during the forecast period.

North America is expected to dominate the overall antipsychotic drugs market:

Among all the regions, North America is expected to dominate the antipsychotic drugs market in the year 2023 and is expected to do the same during the forecast period from 2024 to 2030.

This can be ascribed to the increasing demand for antipsychotic drugs in the region owing to the increasing prevalence of various mental disorders in the region. Further, the rising burden of geriatric patients, the presence of key domicile players in the region, surging drug approvals and launches, and others are among key factors that contribute to the growth of the antipsychotic drugs market in North America during the forecast period from 2024 to 2030.

As per the latest study conducted by the National Alliance on Mental Illness, 1 in 5 US adults experience mental illness each year and 1 in 20 US adults experience serious mental illness each year. Further, 1 in 6 US youth aged 6-17 experience a mental health disorder each year on average. As per Depression and Bipolar Support Alliance 2022, bipolar disorder affects approximately 5.7 million adult Americans or about 2.6% of the US population aged 18 and older every year.

Thus, the rising prevalence of mental disorders such as bipolar disorder, dementia, depression, and others will propel the demand for antipsychotic drugs during the forecast period. Additionally, the rising burden of geriatric patients prone to mental disorders is also going to propel the demand for antipsychotic drugs in the region.

The market players in the North American region are continuously concentrating on the development of novel drugs to tackle mental disorder indications using antipsychotic drugs, and they are also adopting various strategies to develop better drugs with reduced side effects. For instance, in April 2023, Teva Pharmaceuticals and MedinCell announced that the U.S. Food and Drug Administration (FDA) granted approval for its UZEDY (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults. UZEDY is the first subcutaneous, long-acting risperidone formulation, utilizing MedinCell's proprietary SteadyTeq copolymer technology to ensure controlled, steady release of the active compound. This technology allows for therapeutic blood concentrations to be achieved within 6 to 24 hours following a single dose.

Also, in September 2022, Zydus Lifesciences' US subsidiary Zydus Pharmaceuticals (USA) Inc. received final approval from the United States Food and Drug Administration (USFDA) to market Cariprazine Capsules, USP 1.5 mg, 3 mg, 4.5 mg, and 6 mg. Cariprazine is an atypical antipsychotic indicated for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar disorder.

Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North America region in the antipsychotic drugs market during the forecast period from 2024 to 2030.

Antipsychotic Drugs Market key players:

Some of the key market players operating in the Antipsychotic Drugs market Eli Lily and Company, Janssen Global Services, LLC, Pfizer Inc, Otsuka Pharmaceutical Co., Ltd, Alkermes, Inc, Dr. Reddy's Laboratories Ltd, AbbVie Inc, Sun Pharmaceutical Industries Ltd, Amneal Pharmaceuticals LLC, Alvogen, Hikma Pharmaceuticals PLC, Viatris Inc, Bayer AG, Bristol-Myers Squibb Company, Cardinal Health Inc, Sanis Health Inc, H. Lundbeck A/S, Elikem Pharmaceuticals Pvt Ltd, Devlife Corporation Private Limited, GSK plc, and others.

Recent Developmental Activities in the Antipsychotic Drugs Market:

• In April 2024, Vanda Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved Fanapt (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar disorder in adults. Fanapt, an atypical antipsychotic agent, had previously been utilized for the acute treatment of schizophrenia in patients.
• In November 2021, Teva Pharmaceuticals announced positive results for a Phase III trial on a subcutaneous, long-acting injectable risperidone formulation in the treatment of schizophrenia.
• In November 2021, Neurocrine Biosciences partnered with Sosei Group Corporation to develop a new brand of protein inhibitor that helped to improve treatments for a wide range of neuropsychiatric disorders. Under the agreement, Neurocrine Biosciences had the right to develop and produce muscarinic M4, M1, and dual M1/M4 receptor agonists discovered by Sosei Heptares.

Key Takeaways from the Antipsychotic Drugs Market Report Study

• Market size analysis for current antipsychotic drugs market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the antipsychotic drugs market.
• Various opportunities available for the other competitors in the antipsychotic drugs market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current antipsychotic drugs market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for antipsychotic drugs market growth in the coming future?

Target audience who can be benefited from this Antipsychotic Drugs Market Report Study

• Antipsychotic drugs providers
• Research organizations and consulting companies
• Antipsychotic drugs related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in antipsychotic drugs
• Various end-users who want to know more about the antipsychotic drugs market and the latest developments in the antipsychotic drugs market.

Frequently Asked Questions for the Antipsychotic Drugs Market:

1. What are Antipsychotic Drugs?

The antipsychotic drugs are prescribed as short or long-term treatment of mental health problems. These drugs help alleviate and control psychotic symptoms such as anxiety, depression, delusions, hallucinations, or mania.

2. What is the market for antipsychotic drugs?

The antipsychotic drugs market was valued at USD 13,404.76 million in 2023 and is likely to register a CAGR of 6.62% during the forecast period from 2024 to 2030 to reach USD 19,653.29 million by 2030.

3. What are the drivers for the antipsychotic drugs market?

The antipsychotic drugs market is experiencing significant growth, driven by the growing prevalence of mental disorders, increasing geriatric population base prone to mental related ailments, increasing focus of governments and health care organizations on mental health, surging new drug launches and approvals, presence of key players in the market, and others which will create an exigency for the antipsychotic drugs. Therefore, the market for antipsychotic drugs is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

4. Who are the key players operating in the antipsychotic drugs market?

Some of the key market players operating in antipsychotic drugs market include Eli Lily and Company, Janssen Services, LLC, Pfizer Inc, Otsuka Pharmaceutical Co., Ltd, Alkermes, Inc, Dr. Reddy's Laboratories Ltd, AbbVie Inc, Sun Pharmaceutical Industries Ltd, Amneal Pharmaceuticals LLC, Alvogen, Hikma Pharmaceuticals PLC, Viatris Inc, Bayer AG, Bristol-Myers Squibb Company, Cardinal Health Inc, Sanis Health Inc, H. Lundbeck A/S, Elikem Pharmaceuticals Pvt Ltd, Devlife Corporation Private Limited, GSK plc, and others.

5. Which region has the highest share in the antipsychotic drugs market?

Among all the regions, North America is estimated to hold a significant revenue share in the antipsychotic drugs market. This can be ascribed to the increasing demand for antipsychotic drugs among patients in the region owing to the increasing prevalence of various mental disorders such as depression, bipolar disorders, substance-induced psychoses, schizophrenia, and others. Further, the rising burden of geriatric patients and the presence of key domicile players in the region act as supportive factors for the North America antipsychotic drugs market growth during the forecast period from 2024 to 2030.

Table of Contents

1. Antipsychotic Drugs Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Antipsychotic Drugs Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Antipsychotic Drugs Market Key Factors Analysis

• 5.1. Antipsychotic Drugs Market Drivers
  • 5.1.1. Growing prevalence of mental disorders
  • 5.1.2. Increasing geriatric population base prone to mental-related ailments
  • 5.1.3. Rising focus of governments and healthcare organizations on mental health
• 5.2. Antipsychotic Drugs Market Restraints and Challenges
  • 5.2.1. High cost of drug development and launches
  • 5.2.2. Addiction caused due to antipsychotic drugs
  • 5.2.3. Stringent regulatory approval process
• 5.3. Antipsychotic Drugs Market Opportunities
  • 5.3.1. Availability of a robust product portfolio of antipsychotic drugs
  • 5.3.2. Increasing investments in R&D activities for antipsychotic drugs

6. Antipsychotic Drugs Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Antipsychotic Drugs Market Assessment

• 7.1. By Indication
  • 7.1.1. Schizophrenia
  • 7.1.2. Bipolar Disorder
  • 7.1.3. Unipolar Disorder
  • 7.1.4. Dementia
  • 7.1.5. Others
• 7.2. By Drug Class
  • 7.2.1. First-Generation or Typical Antipsychotics
    • 7.2.1.1. Haloperidol
    • 7.2.1.2. Prochloraperazine
    • 7.2.1.3. Others
  • 7.2.2. Second-Generation or Atypical Antipsychotics
    • 7.2.2.1. Clozapine
    • 7.2.2.2. Risperidone
    • 7.2.2.3. Others
  • 7.2.3. Third Generation
    • 7.2.3.1. Abilify (Aripiprazole)
    • 7.2.3.2. Others
• 7.3. By Distribution Channel
  • 7.3.1. Hospital Pharmacy
  • 7.3.2. Retail Pharmacy
  • 7.3.3. E-commerce
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Antipsychotic Drugs Market Size in USD million (2021-2030)
    • 7.4.1.2. Canada Antipsychotic Drugs Market Size in USD million (2021-2030)
    • 7.4.1.3. Mexico Antipsychotic Drugs Market Size in USD million (2021-2030)
  • 7.4.2. Europe
    • 7.4.2.1. France Antipsychotic Drugs Market Size in USD million (2021-2030)
    • 7.4.2.2. Germany Antipsychotic Drugs Market Size in USD million (2021-2030)
    • 7.4.2.3. United Kingdom Antipsychotic Drugs Market Size in USD million (2021-2030)
    • 7.4.2.4. Italy Antipsychotic Drugs Market Size in USD million (2021-2030)
    • 7.4.2.5. Spain Antipsychotic Drugs Market Size in USD million (2021-2030)
    • 7.4.2.6. Rest of Europe Antipsychotic Drugs Market Size in USD million (2021-2030)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Antipsychotic Drugs Market Size in USD million (2021-2030)
    • 7.4.3.2. Japan Antipsychotic Drugs Market Size in USD million (2021-2030)
    • 7.4.3.3. India Antipsychotic Drugs Market Size in USD million (2021-2030)
    • 7.4.3.4. Australia Antipsychotic Drugs Market Size in USD million (2021-2030)
    • 7.4.3.5. South Korea Antipsychotic Drugs Market Size in USD million (2021-2030)
    • 7.4.3.6. Rest of Asia-Pacific Antipsychotic Drugs Market Size in USD million (2021-2030)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Antipsychotic Drugs Market Size in USD million (2021-2030)
    • 7.4.4.2. Africa Antipsychotic Drugs Market Size in USD million (2021-2030)
    • 7.4.4.3. South America Antipsychotic Drugs Market Size in USD million (2021-2030)

8. Antipsychotic Drugs Market Company and Product Profiles

• 8.1. Eli Lily and Company
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Janssen Global Services, LLC
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Pfizer Inc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Otsuka Pharmaceutical Co., Ltd
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Alkermes, Inc
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Dr. Reddy's Laboratories Ltd
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. AbbVie Inc
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Sun Pharmaceutical Industries Ltd
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Amneal Pharmaceuticals LLC
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Alvogen
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Hikma Pharmaceuticals PLC
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Viatris Inc
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Bayer AG
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Bristol-Myers Squibb Company
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Cardinal Health Inc
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Sanis Health Inc
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Lundbeck A/S
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Elikem Pharmaceuticals Pvt Ltd
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Devlife Corporation Private Limited
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. GSK plc.
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us